Powder Or Dust Containing Patents (Class 424/46)
  • Patent number: 8182838
    Abstract: The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: May 22, 2012
    Assignee: Vectura Limited
    Inventors: David Morton, John Staniforth
  • Patent number: 8182791
    Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: May 22, 2012
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
  • Patent number: 8182792
    Abstract: A process for micronization of pharmaceutically active agents.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: May 22, 2012
    Assignee: Novartis AG
    Inventors: Gerhard Muhrer, Ricardo Schneeberger, Wolfgang Wirth, Anton Baumberger
  • Publication number: 20120111324
    Abstract: The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: October 22, 2008
    Publication date: May 10, 2012
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Edward R. Kraft, Stephen L. Hoskins, Perenlei Enkhbaatar, Daniel L. Traber
  • Patent number: 8173107
    Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: May 8, 2012
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Patent number: 8168223
    Abstract: Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: May 1, 2012
    Assignee: Novartis Pharma AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
  • Patent number: 8158109
    Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 17, 2012
    Assignee: Stiefel Research Australia Pty Ltd
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 8158110
    Abstract: The present invention relates to methods and compositions for prevention of graft rejection in lung transplant recipients and for treatment of subjects with pulmonary disorders. Specifically, the methods and compositions of the invention provide a means for inhibiting immune response mediated inflammatory processes in the lungs. The method of the invention comprises the administration of aerosolized cyclosporine for prevention of acute and/or chronic refractory rejection in lung transplant patients. The invention further provides for the use of aerosolized cyclosporine to treat subjects having immunologically mediated inflammatory pulmonary disorders including, but not limited to, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis and allergic rhinitis.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: April 17, 2012
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Aldo T. Iacono, Griffith Bartley
  • Patent number: 8153104
    Abstract: The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patient. In particular, the invention provides a formulation comprising microparticles constituted of microparticles of a low-dosage strength active ingredient and microparticles of an excipient wherein the MMD of the microparticles is comprised between 2 and 15 micron, at least 10% of the microparticles has a mass diameter (MD) higher than 0.5 micron, and the process of preparation thereof.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: April 10, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Roberto Bilzi, Angela Armanni, Roberto Rastelli, Daniela Cocconi, Rosella Musa
  • Patent number: 8137683
    Abstract: The present invention relates to a process of a dispersion of an active substance or composition in a aqueous phase which comprises dispersing in an aqueous phase a solution of such substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing the mixture and separating the dispersion from the gaseous solvent.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: March 20, 2012
    Assignee: DSM IP Assets B.V.
    Inventor: David Schaffner
  • Patent number: 8137657
    Abstract: In a method of producing particles suitable for use as carrier particles in dry powder inhalers, particles (1) of a size suitable for use as carrier particles in dry powder inhalers are treated so as to dislodge small grains from the surface of the particles, without substantially changing the size of the particles during the treatment. The treatment gives improved efficiency of redispersion of active particles from the surfaces of carrier particles.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: March 20, 2012
    Assignee: Vectura Limited
    Inventor: John Nicholas Staniforth
  • Patent number: 8129364
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: March 6, 2012
    Assignee: Dey Pharma, L.P.
    Inventor: Imtiaz Chaudry
  • Patent number: 8124128
    Abstract: An amphiphilic block copolymer. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nano particle and carrier comprising the amhpiphilic block copolymer for delivery of water-insoluble drugs, growth factors, genes, or cosmetic substances.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: February 28, 2012
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Fa Hsieh, Hsuen-Tseng Chang, Chin-Fu Chen, Yuan-Chia Chang, Pei Kan, Tsai-Yu Lin, Yuan-Hung Hsu
  • Patent number: 8119105
    Abstract: The invention relates to an aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas. The aerosol container has a metering valve that comprises a metering chamber and a valve stem. In a first position of the valve stem, the metering chamber is in communication with the interior of the container and has been filled with a predetermined amount of the aerosol. In a second position of the valve stem, the amount of aerosol disposed in the metering chamber is released. The propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons, and the inner wall of the container is coated with a plastics coating.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: February 21, 2012
    Assignee: Novartis Corporation
    Inventors: Francois Brugger, Angelika Stampf
  • Publication number: 20120039818
    Abstract: A composition and method which prevents or mitigates irritation on the skin of a subject by protecting against or relieving chafing, itching and moisture, and which provides a cooling sensation where applied.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 16, 2012
    Inventors: Timothy C. Joyce, James Hammer
  • Patent number: 8114438
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: February 14, 2012
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 8101160
    Abstract: A formulation for use in an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; fine particles of an excipient material having a mass median aerodynamic diameter of not more than 20 ?m; and active particles. The formulation has excellent flowability even at relatively high contents of fine particles.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: January 24, 2012
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton
  • Patent number: 8092785
    Abstract: Drug substance for use in a pharmaceutical formulation may be prepared by a process which process comprises co-milling a suspension of the drug substance and a pharmaceutically acceptable polymer in a liquid propellant.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: James Matthew Butler, Angus Harry Forster, James Edon Patterson, John Peter Warr
  • Patent number: 8080236
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formulation containing a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m. The particles may be suspended in a nonsolvent hydrofluorocarbon fluid vehicle (e.g., HFA 134a or 227ea) at a concentration within a range from about 0.2% w/v to about 5% w/v. The formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the vehicle. The particulate active substance may contain salmeterol xinafoate, budesonide, salbutamol sulfate, dihydroergotamine mesylate, risperidone-(9-hydroxy)-palmitate, bromocriptine mesylate, or derivatives thereof. In some examples, the active substance is dihydroergotamine mesylate.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: December 20, 2011
    Assignee: Nektar Therapeutics UK, Ltd
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 8074644
    Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000° C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10? thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: December 13, 2011
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Ron L. Hale, Craig C. Hodges, Peter M. Lloyd, Daniel Mufson, Daniel D. Rogers, Soonho Song, Martin J. Wensley, Daniel J. Myers, Jeffrey A. McKinney, Reynaldo J. Quintana, Joshua D. Rabinowitz
  • Patent number: 8075873
    Abstract: The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second particulate inhalant medicament. Also provided are dry powder compositions and methods of using them with a dry powder inhalation device.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: December 13, 2011
    Assignee: Norton Healthcare Limited
    Inventor: Xian-Ming Zeng
  • Patent number: 8071074
    Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: December 6, 2011
    Assignee: The Regents of the University of California
    Inventors: Jay A. Nadel, Kiyoshi Takeyama
  • Publication number: 20110293680
    Abstract: The present invention relates to a composition of a temporary hair thickener. In particular, the present invention relates to a composition of a temporary hair thickener comprising bamboo charcoal powder, a hydrophobic waterproof coating agent, a low grade alcohol and a propellant in a specific amount. The composition of a temporary hair thickener in accordance with the present invention can be attached to hair for a longer time as compared with the prior art hair thickeners, thereby showing improved persistency. Further, since the thickener ingredients of the composition are hardly flowed down or detached from hairs by rain or sweat, the composition of the present invention solves the problem of blotting the skin and clothes.
    Type: Application
    Filed: July 20, 2009
    Publication date: December 1, 2011
    Applicant: DONG SUNG PHARM. CO., LTD.
    Inventors: Bong-Lim Jo, Hye-Jin Moon
  • Patent number: 8062626
    Abstract: The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim KG
    Inventors: Bernhard Freund, Michael Krueger, Bernd Zierenberg
  • Patent number: 8062670
    Abstract: Powder compositions exhibiting improved flow properties. The compositions generally contain a bulk solid material in the form of a powder and surface-modified nanoparticles. Methods of improving the flow of powder compositions and devices and articles made using such compositions are also disclosed.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: November 22, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Jimmie R. Baran, Jr., Stephen W. Stein, James S. Stefely, Madeline P. Shinbach
  • Patent number: 8062627
    Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: November 22, 2011
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Gunnar Aberg, John Morley
  • Patent number: 8048451
    Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: November 1, 2011
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
  • Publication number: 20110262502
    Abstract: The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend.
    Type: Application
    Filed: July 1, 2011
    Publication date: October 27, 2011
    Applicant: Prairie Pharmaceuticals LLC
    Inventors: Chang LEE, Tao Tom Du
  • Patent number: 8034817
    Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 11, 2011
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton
  • Patent number: 8029768
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: October 4, 2011
    Assignee: Sosei R&D Ltd.
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Patent number: 8022082
    Abstract: An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 ?{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 ?m, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 ?m to 500 ?m, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 ?{square root over (kPa)} min/L containing the inhalable powder.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: September 20, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventor: Bernd Zierenberg
  • Patent number: 8017237
    Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: September 13, 2011
    Assignee: Abbott Cardiovascular Systems, Inc.
    Inventors: Florian Niklas Ludwig, Stephen D. Pacetti, Syed F. A. Hossainy, Dariush Davalian
  • Publication number: 20110206771
    Abstract: Provided is an encapsulated functional fine particle composition capable of spraying that is useful for hemostasis and wound protection and allows a patient to treat the wound by oneself. Additionally, the composition can be rapidly applied on a large wound during an operation using an air gun in case of in-vivo application and shows prompt hemostasis.
    Type: Application
    Filed: October 30, 2009
    Publication date: August 25, 2011
    Applicant: GENEWEL CO., LTD
    Inventors: Jin-suk Choi, Young-woo Lee, Jun-ho Kim, Eun-young Shim
  • Patent number: 8003081
    Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 23, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton, William R. Baker
  • Patent number: 8001961
    Abstract: A container for liquid inhalation anesthetics, more particularly, an aluminum container that is suitable for storing halogenated inhalation anesthetics is described.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: August 23, 2011
    Assignee: Baxter International Inc.
    Inventors: Ralph V. Rudzinski, Ralph A. Lessor
  • Patent number: 8003080
    Abstract: The present invention relates to the delivery of drug amines through an inhalation route. Specifically, it relates to aerosols containing drug amines that are used in inhalation therapy. In one aspect of the present invention, a method of delivering an amine drug in an aerosol form is provided. The method comprises: a) heating a coating, which includes an amine drug salt on a substrate contained in a device to a temperature sufficient to volatilize the amine drug from the coating, b) by said heating, forming an amine drug vapor, and c) during said heating, drawing air through said device, condensing said vapor to form aerosol particles containing less than 10% degradation products of the compound.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: August 23, 2011
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Patent number: 7998463
    Abstract: An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline and nebulized into an aerosol having a mass median aerodynamic diameter 3 ?m to 10 ?m and a geometric standard deviation less than 1.7 using an electronic nebulizer.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 16, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton
  • Patent number: 7988952
    Abstract: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a method aspect of the present invention, a drug ester is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises a drug ester, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug ester degradation product. In a kit aspect of the present invention, a kit for delivering a drug ester through an inhalation route is provided which comprises: a) a thin coating of a drug ester composition and b) a device for dispensing said thin coating as a condensation aerosol.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: August 2, 2011
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Patent number: 7972626
    Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is fluticasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is fluticasone propionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: July 5, 2011
    Assignee: Merck Patent GmbH
    Inventor: Imtiaz Chaudry
  • Patent number: 7972627
    Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: July 5, 2011
    Assignee: Merck Patent GmbH
    Inventor: Imtiaz Chaudry
  • Patent number: 7954491
    Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: June 7, 2011
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Jeffrey S. Hrkach
  • Patent number: 7951401
    Abstract: New solid drug dispersions are described in which a drug is present in amorphous form and dispersed within the particles of an organic carrier selected from cross-linked polymers and/or complexing agents. These dispersions are obtainable by mixing the drug and the carrier and applying an oscillating electromagnetic field in the microwave region according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: May 31, 2011
    Assignee: Eurand S.p.A.
    Inventors: Italo Colombo, Dario Gervasoni
  • Patent number: 7947744
    Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: May 24, 2011
    Assignee: Nycomed GmbH
    Inventor: Ruth Margaret Wayland
  • Patent number: 7947308
    Abstract: Effervescent powders comprising inhalable particles are disclosed, as are methods for preparing these powders. The inhalable carrier particles comprise an inorganic or organic carbonate, and an acid, and exhibit effervescence when exposed to water or humid air. The particles have a mass median aerodynamic diameter suitable for nasal, bronchial, or pulmonary administration. The inhalable particles may be used as carriers for active agents. The inhalable particles may also be used to enhance permeability of mucosal and surface barriers on an inner surface of the nose, mouth, airway, and/or lungs of a patient, as well as to loosen, thin, cleanse, and remove mucus and extrinsic surface materials from an inner surface of the nose, mouth, airway, and/or lungs of a patient in need thereof.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: May 24, 2011
    Inventors: Raimar Loebenberg, Warren H. Finlay, Wilson H. Roa, Leticia Ely
  • Patent number: 7947742
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: May 24, 2011
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 7943178
    Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: May 17, 2011
    Assignee: MannKind Corporation
    Inventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
  • Patent number: 7943118
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: May 17, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Publication number: 20110097281
    Abstract: The present invention relates to a formulation comprising an aqueous emulsion and a blowing agent for a foaming skin cream, a distinctive feature thereof being that the emulsion comprises microsilver.
    Type: Application
    Filed: May 12, 2009
    Publication date: April 28, 2011
    Inventor: Thomas Neubourg
  • Publication number: 20110097282
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: December 30, 2010
    Publication date: April 28, 2011
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Patent number: 7914771
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Philip A. Pemberton, Helen L. Gibson